At a glance
ClinicalIndex Comparison RecordPhase 2Active· 51 enrolled
Drug / intervention
Durvalumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter Phase II Trial of Durvalumab (MEDI4736) With Trastuzumab and Pertuzumab Combination in HER2-Enriched and HER2-Amplified Breast Cancer (DTP Trial)
In Brief
A Phase 2 clinical trial evaluating Durvalumab, Trastuzumab, and 1 other intervention for Breast Cancer. Active but no longer recruiting, targeting 51 participants across 1 site.
Detailed Summary
The purpose of this research study is to test the safety and effectiveness of using durvalumab with trastuzumab and pertuzumab in participants with human epidermal growth factor receptor 2 (HER2)-enriched breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsAstraZeneca
Timeline
Phase 2Active
20192020202120222023202420252026202720282029
First PostedJan 2019
Enrollment StartJun 2020
Primary CompletionOct 2024
TodayJul 2026
Study CompletionDec 2028
First PostedJan 29, 2019
Enrollment StartJun 30, 2020
Primary CompletionOct 30, 2024
Study CompletionDec 1, 2028
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 7.4 years ago
Interventions
Durvalumabdrug
programmed cell death-ligand 1 inhibitor
Trastuzumabdrug
anti-HER2 monoclonal antibody
Pertuzumabdrug
anti-HER2 monoclonal antibody